Literature DB >> 26442832

Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma.

Katarina Mirjačić Martinović1, Tatjana Srdić-Rajić1, Nada Babović2, Radan Džodić3, Vladimir Jurišić4, Gordana Konjević5.   

Abstract

AIMS: As numerous signalling molecules regulate effector functions of peripheral blood lymphocytes (PBLs) that have an important anti-tumour activity, the aim of this study was to analyse their level in patients with metastatic melanoma (MM) compared with healthy controls (HCs).
METHODS: Peripheral blood mononuclear cells (PBMCs) of 36 MMs and 28 HCs were analysed for the level of perforin, interferon-regulating transcription factor-1 (IRF-1), DAP10 and Src homology 2 domain-containing tyrosine phosphatase-1 by reverse transcriptase PCR, level of phosphorylated signal transducers and activators of transcription (pSTAT)-1, pSTAT-4, pSTAT-5 by western blot and interferon (IFN)-γ production by ELISA. The expression of activating NKG2D and inhibitory killer immunoglobulin-like receptors (KIR), CD158a and CD158b, on PBL, CD3-CD56+ natural killer (NK) cells and CD3+CD8+ cytotoxic T lymphocytes (CTLs), as well as the percentage of CD14+HLA-DR- cells in PBMC were estimated by flow cytometry.
RESULTS: Patients with MM, compared with HCs, had significantly lower level of cytotoxic molecule perforin and decreased IFN-γ production, as well as lower level of pSTAT-1, pSTAT-4, pSTAT-5 and IRF-1 signalling molecules in PBMC. Furthermore, MM had decreased expression of activating NKG2D receptor on PBL and NK cells and low level of its DAP10 signalling molecule contrary to no changes in KIR expression on all investigated cells. These results could be associated with increased percentage of immunosuppressive CD14+HLA-DR- myeloid-derived suppressor cells detected in patients with MM.
CONCLUSIONS: The altered signalling molecules of PBL could represent biomarkers of impaired cytotoxic and immunoregulatory function of these cells, indicating melanoma-associated immunosuppression that facilitates tumour progression. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  CELL CYCLE REGULATION; IMMUNOPHENOTYPING; MELANOMA

Mesh:

Substances:

Year:  2015        PMID: 26442832     DOI: 10.1136/jclinpath-2015-203107

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.

Authors:  Louise M E Müller; Matthew Holmes; Joanne L Michael; Gina B Scott; Emma J West; Karen J Scott; Christopher Parrish; Kathryn Hall; Sina Stäble; Victoria A Jennings; Matthew Cullen; Stewart McConnell; Catherine Langton; Emma L Tidswell; Darren Shafren; Adel Samson; Kevin J Harrington; Hardev Pandha; Christy Ralph; Richard J Kelly; Gordon Cook; Alan A Melcher; Fiona Errington-Mais
Journal:  J Immunother Cancer       Date:  2019-07-01       Impact factor: 13.751

2.  Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC.

Authors:  Kelvin Anderson; Nathan Ryan; Greta Volpedo; Sanjay Varikuti; Abhay R Satoskar; Steve Oghumu
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

3.  A Pyroptosis-Related Gene Signature Predicts Prognosis and Immune Microenvironment for Breast Cancer Based on Computational Biology Techniques.

Authors:  Zitao Wang; Anyu Bao; Shiyi Liu; Fangfang Dai; Yiping Gong; Yanxiang Cheng
Journal:  Front Genet       Date:  2022-04-07       Impact factor: 4.772

4.  IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway.

Authors:  Min Hong; Zuoyang Zhang; Qing Chen; Yanxia Lu; Jianming Zhang; Chun Lin; Fan Zhang; Wenjuan Zhang; Xiaomin Li; Wei Zhang; Xuenong Li
Journal:  Cancer Manag Res       Date:  2018-12-31       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.